RECURSION PHARMACEUTICALS, INC. business relationships
Companies named in RECURSION PHARMACEUTICALS, INC.’s 10-K filed 2026-02-25, and public companies whose annual reports name RECURSION PHARMACEUTICALS, INC.. Each link shows the sentence it came from. Scores are Engagemii’s AI visibility scores.
- AEO visibility
- 7.7 / 10
- AI naming
- 100 / 100 Top 1% in its category
- Agent readiness
- 5 / 100
- AI adoption
- 14 / 100
Named in RECURSION PHARMACEUTICALS, INC.’s annual report 15
“Bayer may terminate each such license agreement at any time without cause.” SEC filing
“In December 2021, Recursion entered into a collaboration and license agreement with Roche and Genentech (collectively referred to as Roche).” SEC filing
“As a result, REC-4881 was in-licensed from Takeda and subsequently advanced into preclinical studies.” SEC filing
“In November 2023, we announced an amended and restated collaboration with Bayer.” SEC filing
“In September 2023, we entered into a collaboration with Merck KGaA, Darmstadt, Germany.” SEC filing
“We largely train models using our own supercomputer, BioHive-2, one of the largest supercomputers in biopharma, built in collaboration with NVIDIA.” SEC filing
“Under the collaboration, Roche and Genentech may initiate up to forty (40) small molecule programs.” SEC filing
“During a collaboration with Takeda, we leveraged machine learning and automated analysis to quantify hundreds of cellular parameters linked to APC siRNA knockdown.” SEC filing
“In January 2022, we entered into a Collaboration and License Agreement, with Sanofi, or the CLA, and in July 2023 and December 2023, we amended the Collaboration and License Agreement, with such as amended CLA referred to as the Amended CLA.” SEC filing
“For the year ended December 31, 2025, the increase in revenue compared to the prior year was due to revenue recognized from our partnership with Sanofi.” SEC filing
“We rely on third-party data centers and telecommunications solutions, including cloud infrastructure services such as Google Cloud and Amazon Web Services, to host substantial portions of our technology platforms and to support our business operations.” SEC filing
“In October 2024, we announced an expanded collaboration with Google Cloud leveraging their technologies to accelerate drug discovery research and further enhance our ability to bring new medicines to patients faster.” SEC filing
“We rely on third-party data centers and telecommunications solutions, including cloud infrastructure services such as Google Cloud and Amazon Web Services, to host substantial portions of our technology platforms and to support our business operations.” SEC filing
“On December 5, 2021, we entered into a Collaboration and License Agreement with Genentech, Inc. and F.” SEC filing
“Under the collaboration, Roche and Genentech may initiate up to forty (40) small molecule programs.” SEC filing
Links are read automatically from public company filings, so every link carries the sentence it came from.
Not investment advice. Scores, rankings and connections are automated estimates from public sources, provided as is. Connections are read automatically from public company filings and may be incomplete or wrong. To correct or remove a company page or a connection, email [email protected]. Company names and logos belong to their owners. Showing them does not mean the company endorses Engagemii or that Engagemii endorses it. Terms